Cancer Communications | Home page

Cancer Communications | Home page

Cancer Communications

Affiliated with

• 
• 
• Cancer Communications is affiliated with Chinese Anti-Cancer Association and US Chinese Anti-Cancer Association.

Articles

• Recent
• Most accessed
• Collections

1. Content type:Mini Review

   22 October 2019

   New frontiers in proton therapy: applications in cancers

   Authors:Tai-Ze Yuan, Ze-Jiang Zhan and Chao-Nan Qian
2. Content type:Original article

   21 October 2019

   Prognosis of lymphotropic invasive micropapillary breast carcinoma analyzed by using data from the National Cancer Database

   Authors:Gary D. Lewis, Yan Xing, Waqar Haque, Tejal Patel, Mary Schwartz, Albert Chen, Andrew Farach, Sandra S. Hatch, E. Brian Butler, Jenny Chang and Bin S. Teh
3. Content type:Original article

   16 October 2019

   Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience

   Authors:Jianhong Peng, Weihao Li, Rongxin Zhang, Junzhong Lin, Jinghua Tang, Yongshan Wen, Zhenhai Lu, Xiaojun Wu and Zhizhong Pan
4. Content type:Original article

   16 October 2019

   Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study

   Authors:Sung Yong Oh, Won Seog Kim, Jin Seok Kim, Seok Jin Kim, Dok Hyun Yoon, Deok-Hwan Yang, Won Sik Lee, Hyo Jung Kim, Ho-Young Yhim, Seong Hyun Jeong, Jong Ho Won, Suee Lee, Jee Hyun Kong, Sung-Nam Lim, Jun Ho Ji, Kyung A. Kwon…
5. Content type:Letter to the Editor

   11 October 2019

   Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study

   Authors:Wen Cai, Biao Cai, Juan Zhou, Yonghui Chen, Jin Zhang, Yiran Huang, Wei Xue and Jiwei Huang